First Bank & Trust Grows Holdings in Sanofi $SNY

First Bank & Trust raised its stake in Sanofi (NASDAQ:SNY) by 23.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 83,933 shares of the company’s stock after acquiring an additional 15,937 shares during the period. First Bank & Trust’s holdings in Sanofi were worth $3,581,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Advisory Services Network LLC lifted its holdings in shares of Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the period. Savant Capital LLC increased its stake in Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after buying an additional 225 shares during the period. Wesbanco Bank Inc. increased its stake in Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after buying an additional 230 shares during the period. IFG Advisory LLC raised its position in Sanofi by 2.7% during the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after buying an additional 244 shares during the last quarter. Finally, Cohen Investment Advisors LLC raised its position in Sanofi by 2.9% during the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after buying an additional 263 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Wall Street Zen downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Sunday. Morgan Stanley set a $49.00 price objective on Sanofi in a report on Wednesday, July 8th. Finally, Citigroup reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Price Performance

Sanofi stock opened at $43.48 on Tuesday. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm’s 50-day simple moving average is $43.32 and its 200 day simple moving average is $45.03. The firm has a market capitalization of $105.41 billion, a PE ratio of 22.76, a P/E/G ratio of 1.08 and a beta of 0.35.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.